4 Stocks Trading Near 52-Week High With More Upside Potential

Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and trend reversals. 

Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculation is not completely baseless, not all stocks hitting a 52-week high are necessarily overpriced.

Investors might lose out on top gainers in an attempt to avoid the steep prices.

Stocks such as TD SYNNEX CORP SNX, Ameriprise Financial AMP, Harmony Biosciences HRMY and Newell Brands NWL are expected to maintain their momentum and keep scaling new highs. More information on a stock is necessary to determine whether there is scope for further upside.

Here, we discuss a strategy to find the right stocks. The technique borrows from the basics of momentum investing and bets on “buy high, sell higher.”

52-Week High: A Good Indicator

Many times, stocks that hit a 52-week high fail to scale higher despite having potential. This is because investors fear that the stocks are overvalued and expect the price to crash.

Overvaluation is natural for most of these stocks as investors’ focus (or willingness to pay the premium) has helped them reach this level. But that does not always indicate an impending decline. Factors such as robust sales, surging profit levels, earnings growth prospects and strategic acquisitions, which encouraged investors to bet on these stocks, could keep them motivated if there are no tangible negatives. In other words, the momentum might continue.

Also, when a string of positive developments dominates the market, investors find their underreaction unwarranted, even if there are no company-specific driving forces.

Setting the Right Filters

We ran a screen to zero in on 52-week high stocks (trading near the high level) that hold tremendous upside potential. The screen includes parameters to shortlist stocks with strong earnings growth expectations, sturdy value metrics and price momentum.

Moreover, the screen filters stocks that are relatively undervalued compared to their peers in terms of earnings and sales, ensuring the continuation of their rally for some time.

Current Price/52 Week High >= .80: This is the ratio between the current price and the highest price at which the stock has traded in the past 52 weeks. A value greater than 0.8 implies the stock is trading within 20% of its 52-week high range.

% Change Price – 4 Weeks > 0: This ensures that the stock price has moved north over the past four weeks.

% Change Price – 12 Weeks > 0: This metric guarantees a continued upward price momentum for the stock over the past three months as well.

Price/Sales <= XIndMed: The lower, the better.

P/E using F(1) Estimate <= XIndMed: This metric measures the amount an investor puts into a company to obtain one dollar of earnings. It narrows down the list of stocks to those that are undervalued compared to the industry.

One-Year EPS Growth F(1)/F(0) >= XIndMed: This helps choose stocks that have higher growth rates than the industry. This is a meaningful indicator, as decent earnings growth adds to investor optimism.

Zacks Rank =1: No screening is complete without the Zacks Rank, which has proved its worth since its inception. It is a fundamental truth that stocks with a Zacks Rank #1 (Strong Buy) have always managed to brave adversities and beat the market average. You can see the complete list of today’s Zacks #1 Rank stocks here.

Current Price >= 5: This parameter will help screen stocks that are trading at $5 or higher.

Volume – 20 days (shares) >= 100000: The inclusion of this metric ensures that there is a substantial volume of shares, so trading is easier.

Here are our four picks out of the 21 stocks that made it through the screen:

TD SYNNEX Corp is poised for near-term upside, supported by strong strategic fundamentals across both its business units. Hyve Solutions continues to capitalize on robust hyperscaler AI infrastructure demand, while the Distribution segment maintains broad-based momentum across cybersecurity, cloud, and AI. In June 2026, management issued third-quarter guidance for non-GAAP gross billings of $27.2–$28.2 billion and non-GAAP EPS of $4.25–$4.75. A 9% year-over-year quarterly dividend increase to $0.48 per share further signals durable cash generation capacity. 

In July 2026, TD SYNNEX was named a Fortinet global distributor, unlocking multi-region engagement opportunities across Europe and Asia. August 2026 saw new AI cloud storage and communications partnerships across Asia-Pacific, expanding its international distribution footprint and reinforcing revenue visibility going forward.

The stock has returned 52.8% in the past six months. It has a trailing four-quarter earnings surprise of 21.7%, on average.

Ameriprise Financial heads into the second half of 2026 with strong fundamental tailwinds. Advisor productivity hit a record $1.2 million per advisor, up 12%. Wrap assets of $732 billion, up 19%, reflect deepening client engagement. Firm-wide AUM/A/A advanced to a record $1.8 trillion, up 14%. The Huntington National Bank partnership, bringing 260 advisors and nearly $28 billion in assets, is set to more than offset Comerica-related outflows by the fourth quarter. Ameriprise's July 2026 announcement of $1 billion in technology and AI spend is generating measurable advisor efficiency gains. In June, the firm earned the BISA Technology Innovation Award for its Signature Wealth Program. The declared $1.70 quarterly dividend, backed by the guidance to return 85–90% of operating earnings to shareholders, underscores capital strength.
    
The stock has returned 4.1% in the past six-month period. It delivered a trailing four-quarter earnings surprise of 5.56%, on average. 

Harmony Biosciences entered second-half 2026 on a solid fundamental footing. The company reiterated full-year WAKIX net revenue guidance of $1.0–$1.04 billion, supported by a growing patient base of 8,950 in the second quarter and disciplined commercial execution. The FDA's July 2026 acceptance of the Pitolisant GR NDA, targeting a PDUFA date of April 1, 2027, adds a near-term regulatory catalyst. 

The August 2026 Phase 1 SAD data for orexin-2 agonist BP-205 demonstrated a ~25-hour half-life, rapid onset, and clean tolerability, with Phase 1b initiating in the third quarter of 2026 and Phase 2 studies planned for mid-2027. Six narcolepsy and idiopathic hypersomnia abstracts at SLEEP 2026 in June bolstered franchise credibility. A $962.5 million cash position supports a self-funded pipeline while WAKIX exclusivity holds through 2030.

This stock has surged 3.2% in the past six-month period. It has a trailing four-quarter negative earnings surprise of 13.97%, on average. 

Newell Brands is building a compelling near-term fundamental case. Full-year 2026 guidance has been raised across all key metrics, with net sales expected to grow 1%–2%, normalized operating margin at 10.0%–10.4%, and normalized EPS of 73 cents–77 cents. Operating cash flow guidance has been raised to approximately $400 million. A €40 million planned investment in French operations — spanning automation, AI-driven digitization, and sustainability — signals durable global capability-building. 

Brand momentum is accelerating. Coleman's multi-year partnership with Kane Brown and Sharpie's collaboration with Under Armour open new consumer audiences. A new $800 million revolving credit facility extended to 2031 strengthens liquidity. Third-quarter 2026 guidance of 2%–3% net and core sales growth, with gross productivity savings, points to further near-term margin improvement.

This stock has gained 35.9% in the past six months. It has a trailing four-quarter earnings surprise of 39.98%, on average. 

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research